MedTrace Logo

HER2-directed Biosimilar in Breast Cancer: Real World ePRO

NCT05234021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2024-04-04

No results posted yet for this study

Summary

This project will engage anti-HER2 directed Trastuzumab biosimilar with a novel quality of ePRO and enable comparison of reliable reference real world patient data, thereby creating a basis for analytic research in order to promote the quality and efficiency of treatment

Conditions

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Palleos Healthcare GmbH

    collaborator INDUSTRY

  • OnkoZentrum Zürich AG

    lead OTHER

Principal Investigators

  • Andreas Trojan, M.D. · Seespital Horgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05234021 on ClinicalTrials.gov